Ovarian Cancer -- Identification of Biomarkers for Clear Cell Ovarian Adenocarcinoma -- Ovarian Carcinoma: Diagnostic Immunohistochemistry of MUCIN4 (MUC4) -- Distinguishing Benign from Malignant Complex Adnexal Masses in Ovarian Cancer: Two-Dimensional Power-Doppler Imaging -- Subgroups of Ovarian Carinoma: Identification Using Differential Gene Expression -- Sertoliform Endometrioid Carcinoma of the Ovary: Diagnosis and Prognosis -- Role of MUC16 (CA125) in the Pathogenesis of Epithelial Ovarian Cancer -- Clear Cell Carcinoma of the Ovary: Prognosis Using Cytoreductive Surgery -- Advanced Ovarian Cancer: Prediction of Surgical Outcomes Using Computed Tomography -- Renal Cancer -- Renal Cell Carcinoma: Follow-Up with Magnetic Resonance Imaging After Percutaneous Radiofrequency Ablation -- Metastatic Kidney Cancer: Treatment with Infusional Interleukin-2 Plus Famotidine -- Renal Cell Carcinoma: Preoperative Treatment with Cytokines Followed by Surgery -- Metastatic Renal Cell Carcinoma: Use of Bcl-2 and Fas to Predict Responses to Immunotherapy -- Wilms Tumor: Prognosis Using Microvessel Density -- Urogenitary Tract Cancer -- Adenomatoid Tumor of the Adrenal Gland: Differential Diagnosis Using Immunohistochemistry -- Testicular Cancer: Post-Chemotherapy Retroperitoneal Lymph Node Dissection -- Survivors of Germ-Cell Testicular Cancer: Increased Risk of Second Primary Tumors -- Urinary Bladder Cancer -- Urothelial Bladder Cancer: Screening with Urine-Based Tumor Markers -- Detection of OCT-4 in Bladder Cancer: Role of Cancer Stem Cell -- Cervical Uterine Cancer -- Uterine Cervical Glandular Lesions: Differentiation Using Immunohistochemistry of Mucins -- Uterine Cervical Carcinoma: Preoperative Magnetic Resonance Imaging Staging -- Cancer Imaging and Intracavitary Brachytherapy for Cervical Cancer -- Cervical Cancer: Methods for Assessing the Quality of Life -- Cervical Cancer: Positron Emission Tomography and Positron Emission Tomography/Computed Tomography -- Endometrial Cancer: Indoleamine 2,3-Dioxygenase as a Prognostic Indicator -- Skin Cancer -- Neurofibromatosis Type 1-Associated Malignant Melanoma: Molecular Evidence of Inactivation of the NF1 Gene -- Malignant Melanoma: Localisation and Characterization Using Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography -- Malignant Melanoma Versus Deep Penetrating Nevus: Diagnostic and Prognostic Immunohistochemistry of Dipeptidyl Peptidase IV (Methodology) -- Nonmelanoma Skin Cancer: Use of Epha1 Receptor as a Prognostic Marker -- Leukemia -- Pretreated Chronic Lymphocytic Leukemia: Use of Alemtuzumab -- Multiple Myeloma -- Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma -- Sarcoma -- Low Grade Fibromyxoid Sarcoma: Diagnosis by Detecting FUS-CREB3L2 Fusion Gene Using Reverse Transcription–Polymerase Chain Reaction -- Synovial Sarcoma: Role of TLE1 as a Diagnostic Immunohistochemical Marker -- The Immunohistochemistry of Kaposi’s Sarcoma -- Synovial Sarcoma: Role of Immunohistochemistry and Molecular Genetics in Diagnosis and Prognosis -- Sarcoma: Treatment with Ecteinascidin-743.

This sixth volume in the series Methods of Cancer Diagnosis, Therapy, and Prognosis discusses Ovarian Cancer, Renal Cancer, Urogenitary Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Both standard and emerging therapies for these cancers, written by expert oncologists/pathologists in this field, are included. This fully illustrated volume Identifies biomarkers based on genetic alterations for clear cell ovarian adenocarcinoma. Identifies subgroups of ovarian cancer by using differential gene expression. Includes the application of the power-Doppler imaging for distinguishing benign from malignant complex adrenal masses in ovarian cancer. Emphasizes the advantage of using cytoreduction surgery for diagnosing advanced ovarian cancer. Provides details on the treatment of kidney cancer with radiofrequency ablation, surgery, and chemotherapy. Explains the use of immunohistochemistry for diagnosing adenomatoid tumor of the adrenal gland. Discusses the chemotherapy of testicular cancer and related second primary tumors. Includes the diagnosis of urothelial bladder cancer with urine-based tumor markers. Explains the use of immunohistochemistry and MRI for diagnosing uterine cervical cancer and describes the staging of this cancer using PET alone or PET/CT. Describes the localization of malignant melanoma using FDG-PET/CT. Explains the use of prognostic receptors for nonmelanoma skin cancer. Details the treatment of multiple myeloma using immunotherapy, radiotherapy, and targeted radionuclide therapy. Presents diagnostic immunohistochemistry of synovial and Kaposi's sarcoma. The technological advances presented in this volume are expected to expedite new discoveries and their translation to clinical practice. The field of oncology will benefit the most from these advanced methods, as a combination of therapies and personalized medicine will improve early detection of these different types of cancer. Professor Hayat has summarized the problems associated with the complexities of research publications and has been successful in editing a must-read volume for oncologists, cancer researchers, medical teachers and students of cancer biology.